论文部分内容阅读
目的探讨盐酸氨溴索对慢性阻塞性肺疾病(COPD)急性加重期白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)的作用。方法选择2006年10月至2007年11月住院的慢性阻塞性肺疾病急性加重期患者共72例,根据治疗方案的不同分为A组(治疗组,38例)和B组(常规组,34例),另选择30例健康者为C组(对照组)。B组给予低流量吸氧、控制感染等常规治疗,A组除常规治疗外,加用盐酸氨溴索60 mg,2次/d静脉点滴或雾化吸入治疗,两组疗程均为2周左右,达临床稳定期标准。分别观察各组治疗前、后血清IL-6、TNF-α水平。结果①A组、B组治疗后血清IL-6、TNF-α水平均低于治疗前,差异有统计学意义(P<0.01)。A组治疗后血清IL-6、TNF-α低于B组,两组比较差异有统计学意义(P<0.05);②A组、B组治疗前、后血清IL-6、TNF-α水平均高于C组,差异有统计学意义(P<0.01)。结论盐酸氨溴索能够抑制COPD患者血清IL-6、TNF-α的释放,协同抗感染,对COPD患者的急性期有较好的治疗作用。
Objective To investigate the effect of ambroxol on interleukin-6 (IL-6) and tumor necrosis factor-α (TNF-α) in patients with acute exacerbation of chronic obstructive pulmonary disease (COPD). Methods A total of 72 patients with acute exacerbation of chronic obstructive pulmonary disease hospitalized from October 2006 to November 2007 were divided into group A (treatment group, 38 cases) and group B (control group, 34 Cases), and the other 30 healthy people were chosen as group C (control group). Group B was given low-flow oxygen inhalation, control of infection and other conventional treatment. In addition to routine treatment, group A was treated with ambroxol 60 mg twice a day or nebulized inhalation. The two courses of treatment were about 2 weeks , Up to the standard clinical stability. The levels of serum IL-6 and TNF-α in each group before and after treatment were observed. Results ① The levels of serum IL-6 and TNF-α in group A and group B after treatment were significantly lower than those before treatment (P <0.01). The serum levels of IL-6 and TNF-α in group A were lower than those in group B (P <0.05); ② The levels of IL-6 and TNF-α in group A and group B before and after treatment were significantly lower than those in group B Higher than C group, the difference was statistically significant (P <0.01). Conclusions Ambroxol hydrochloride can inhibit the release of serum IL-6 and TNF-α in patients with COPD and synergize with anti-infection, and has a good therapeutic effect on acute phase of COPD.